RESPIRATORY
BRONCHIECTASIS
|
Question
[CLICK ON ANY CHOICE TO KNOW THE RIGHT ANSWER]
|
Brensocatib showed promising reults in bronchiectasis pt with history of two or more exb in a year, in phase 3 trial is
|
|
antagonist of CXC chemokine receptor 2
|
|
|
oral rev inh of dipeptidyl peptidase inh 1
|
|
|
IL4 inh
|
|
|
neutrophil elastase inh
|
Explanation:
Detailed explanation-1: -Upon oral administration, brensocatib reversibly binds to and inhibits the activity of DPP1, thereby inhibiting the activation of neutrophil serine proteases (NSPs), including neutrophil elastase (NE), during neutrophil maturation.
Detailed explanation-2: -The most common AEs in patients treated with brensocatib were cough, headache, sputum increase, dyspnea, infective exacerbation of bronchiectasis, and diarrhea.
Detailed explanation-3: -Living with bronchiectasis can be stressful and frustrating, but most people with the condition have a normal life expectancy. For people with very severe symptoms, however, bronchiectasis can be fatal if the lungs stop working properly.
There is 1 question to complete.